Skip to main content
Top
Gepubliceerd in:

20-04-2023

Health-state utilities in long-term advanced melanoma survivors comparable with the general population

Auteurs: M. D. Egeler, L. V. van de Poll-Franse, R. Tissier, A. Rogiers, M. J. Boers-Sonderen, A. J. van den Eertwegh, G. A. Hospers, J. W. B. de Groot, M. J. B. Aarts, E. Kapiteijn, D. Piersma, G. Vreugdenhil, A. A. van der Veldt, K. P. M. Suijkerbuijk, B. Neyns, K. J. Janssen, C. U. Blank, V. P. Retèl, A. H. Boekhout

Gepubliceerd in: Quality of Life Research | Uitgave 9/2023

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Background

Checkpoint inhibitors have been shown to substantially improve the survival of patients with advanced melanoma. With this growing group of survivors treated with immunotherapies, assessing their health-state utilities is essential and can be used for the calculation of quality-adjusted life years and for cost-effectiveness analyses. Therefore, we evaluated the health-state utilities in long-term advanced melanoma survivors.

Methods

Health-state utilities were evaluated in a cohort of advanced melanoma survivors 24–36 months (N = 37) and 36-plus months (N = 47) post-ipilimumab monotherapy. In addition, the health-state utilities of the 24–36 months survivor group were assessed longitudinally, and utilities of the combined survival groups (N = 84) were compared with a matched control population (N = 168). The EQ-5D was used to generate health-state utility values, and quality-of-life questionnaires were used to establish correlations and influencing factors of utility scores.

Results

Health-state utility scores were similar between the 24–36 months’- and the 36-plus months’ survival group (0.81 vs 0.86; p = .22). In survivors, lower utility scores were associated with symptoms of depression (β = − .82, p = .022) and fatigue burden (β = − .29, p = .007). Utility scores did not significantly change after 24–36 months of survival, and the utilities of survivors were comparable to the matched control population (0.84 vs 0.87; p = .07).

Discussion

Our results show that long-term advanced melanoma survivors treated with ipilimumab monotherapy experience relatively stable and high health-state utility scores.
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
1.
go back to reference Hodi, F. S., et al. (2018). Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. The Lancet Oncology, 19(11), 1480–1492.CrossRefPubMed Hodi, F. S., et al. (2018). Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. The Lancet Oncology, 19(11), 1480–1492.CrossRefPubMed
2.
go back to reference Hodi, F. S., et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine, 363(8), 711–723.CrossRefPubMed Hodi, F. S., et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine, 363(8), 711–723.CrossRefPubMed
3.
go back to reference Schadendorf, D., et al. (2015). Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. Journal of Clinical Oncology, 33(17), 1889.CrossRefPubMedPubMedCentral Schadendorf, D., et al. (2015). Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. Journal of Clinical Oncology, 33(17), 1889.CrossRefPubMedPubMedCentral
4.
go back to reference Albertini, M. R. (2018). The age of enlightenment in melanoma immunotherapy. Journal for Immunotherapy of Cancer, 6(1), 1–4.CrossRef Albertini, M. R. (2018). The age of enlightenment in melanoma immunotherapy. Journal for Immunotherapy of Cancer, 6(1), 1–4.CrossRef
7.
go back to reference Boekhout, A. H., Rogiers, A., Jozwiak, K., Boers-Sonderen, M. J., van den Eertwegh, A. J., Hospers, G. A., de Groot, J. W. B., Aarts, M. J. B., Kapiteijn, E., Ten Tije, A. J., & Piersma, D. (2021). Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls. Acta Oncologica, 60(1), 69–77.CrossRefPubMed Boekhout, A. H., Rogiers, A., Jozwiak, K., Boers-Sonderen, M. J., van den Eertwegh, A. J., Hospers, G. A., de Groot, J. W. B., Aarts, M. J. B., Kapiteijn, E., Ten Tije, A. J., & Piersma, D. (2021). Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls. Acta Oncologica, 60(1), 69–77.CrossRefPubMed
8.
go back to reference Rogiers, A., Leys, C., De Cremer, J., Awada, G., Schembri, A., Theuns, P., De Ridder, M., & Neyns, B. (2019). Longitudinal pilot study of the Health Related Quality of life, emotional burden and neurocognitive function in the first generation of metastatic melanoma survivors treated with pembrolizumab. Supportive Care in Cancer. https://doi.org/10.1007/s00520-019-05168-3CrossRefPubMed Rogiers, A., Leys, C., De Cremer, J., Awada, G., Schembri, A., Theuns, P., De Ridder, M., & Neyns, B. (2019). Longitudinal pilot study of the Health Related Quality of life, emotional burden and neurocognitive function in the first generation of metastatic melanoma survivors treated with pembrolizumab. Supportive Care in Cancer. https://​doi.​org/​10.​1007/​s00520-019-05168-3CrossRefPubMed
10.
go back to reference Lai-Kwon, J., et al. (2019). The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors. Journal of Cancer Survivorship, 13(4), 503–511.CrossRefPubMed Lai-Kwon, J., et al. (2019). The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors. Journal of Cancer Survivorship, 13(4), 503–511.CrossRefPubMed
11.
go back to reference Michael John Alex, G., & Wyrwich, K. W. (2003). Health utility measures and the standard gamble. Academic emergency medicine, 10(4), 360–363.CrossRef Michael John Alex, G., & Wyrwich, K. W. (2003). Health utility measures and the standard gamble. Academic emergency medicine, 10(4), 360–363.CrossRef
12.
go back to reference Hatswell, A. J., Pennington, B., Pericleous, L., Rowen, D., Lebmeier, M., & Lee, D. (2014). Patient-reported utilities in advanced or metastatic melanoma, including analysis of utilities by time to death. Health and Quality of Life Outcomes, 12(1), 1–9.CrossRef Hatswell, A. J., Pennington, B., Pericleous, L., Rowen, D., Lebmeier, M., & Lee, D. (2014). Patient-reported utilities in advanced or metastatic melanoma, including analysis of utilities by time to death. Health and Quality of Life Outcomes, 12(1), 1–9.CrossRef
13.
go back to reference Reck, M., Taylor, F., Penrod, J. R., DeRosa, M., Morrissey, L., Dastani, H., Orsini, L., & Gralla, R. J. (2018). Impact of nivolumab versus docetaxel on health-related quality of life and symptoms in patients with advanced squamous non–small cell lung cancer: results from the CheckMate 017 study. Journal of Thoracic Oncology, 13(2), 194–204.CrossRefPubMed Reck, M., Taylor, F., Penrod, J. R., DeRosa, M., Morrissey, L., Dastani, H., Orsini, L., & Gralla, R. J. (2018). Impact of nivolumab versus docetaxel on health-related quality of life and symptoms in patients with advanced squamous non–small cell lung cancer: results from the CheckMate 017 study. Journal of Thoracic Oncology, 13(2), 194–204.CrossRefPubMed
14.
go back to reference Hu, X., & Hay, J. W. (2018). First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: A cost-effectiveness analysis from the UK health care perspective. Lung Cancer, 123, 166–171.CrossRefPubMed Hu, X., & Hay, J. W. (2018). First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: A cost-effectiveness analysis from the UK health care perspective. Lung Cancer, 123, 166–171.CrossRefPubMed
15.
go back to reference Miguel, L. S., Lopes, F. V., Pinheiro, B., Wang, J., Ruifeng, X., Pellissier, J., & Laires, P. A. (2017). Cost effectiveness of pembrolizumab for advanced melanoma treatment in Portugal. Value in Health, 20(8), 1065–1073.CrossRefPubMed Miguel, L. S., Lopes, F. V., Pinheiro, B., Wang, J., Ruifeng, X., Pellissier, J., & Laires, P. A. (2017). Cost effectiveness of pembrolizumab for advanced melanoma treatment in Portugal. Value in Health, 20(8), 1065–1073.CrossRefPubMed
16.
go back to reference Tromme, I., Devleesschauwer, B., Beutels, P., Richez, P., Leroy, A., Baurain, J.-F., Cornelis, F., Bertrand, C., Legrand, N., Degueldre, J., Thomas, L., Legrand, C., Lambert, J., Haagsma, J., & Speybroeck, N. (2014). Health-related quality of life in patients with melanoma expressed as utilities and disability weights. British Journal of Dermatology, 171(6), 1443–1450.CrossRefPubMed Tromme, I., Devleesschauwer, B., Beutels, P., Richez, P., Leroy, A., Baurain, J.-F., Cornelis, F., Bertrand, C., Legrand, N., Degueldre, J., Thomas, L., Legrand, C., Lambert, J., Haagsma, J., & Speybroeck, N. (2014). Health-related quality of life in patients with melanoma expressed as utilities and disability weights. British Journal of Dermatology, 171(6), 1443–1450.CrossRefPubMed
17.
go back to reference Randall Patrinely, J., Johnson, R., Lawless, A. R., Bhave, P., Sawyers, A., Dimitrova, M., Yeoh, H. L., Palmeri, M., Ye, F., Fan, R., Davis, E. J., Rapisuwon, S., Long, G. V., Haydon, A., Osman, I., Mehnert, J. M., Carlino, M. S., Sullivan, R. J., Menzies, A. M., & Johnson, D. B. (2021). Chronic immune-related adverse events following adjuvant anti–PD-1 therapy for high-risk resected melanoma. JAMA oncology, 7(5), 744–748.CrossRefPubMed Randall Patrinely, J., Johnson, R., Lawless, A. R., Bhave, P., Sawyers, A., Dimitrova, M., Yeoh, H. L., Palmeri, M., Ye, F., Fan, R., Davis, E. J., Rapisuwon, S., Long, G. V., Haydon, A., Osman, I., Mehnert, J. M., Carlino, M. S., Sullivan, R. J., Menzies, A. M., & Johnson, D. B. (2021). Chronic immune-related adverse events following adjuvant anti–PD-1 therapy for high-risk resected melanoma. JAMA oncology, 7(5), 744–748.CrossRefPubMed
18.
go back to reference Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Lance Cowey, C., Schadendorf, D., Wagstaff, J., Dummer, R., Ferrucci, P. F., Smylie, M., Butler, M. O., Hill, A., Márquez-Rodas, I., Haanen, J. B. A. G., Guidoboni, M., Maio, M., Schöffski, P., … Hodi, S. (2022). Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma,". Journal of Clinical Oncology, 40(2), 127–137.CrossRefPubMed Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Lance Cowey, C., Schadendorf, D., Wagstaff, J., Dummer, R., Ferrucci, P. F., Smylie, M., Butler, M. O., Hill, A., Márquez-Rodas, I., Haanen, J. B. A. G., Guidoboni, M., Maio, M., Schöffski, P., … Hodi, S. (2022). Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma,". Journal of Clinical Oncology, 40(2), 127–137.CrossRefPubMed
19.
go back to reference Robert, C., Thomas, L., Bondarenko, I., O’Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., Davidson, N., Richards, J., Maio, M., Hauschild, A., Miller, W. H., Gascon, P., Lotem, M., Harmankaya, K., Ibrahim, R., … Wolchok, J. D. (2011). Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New England Journal of Medicine, 364(26), 2517–2526.CrossRefPubMed Robert, C., Thomas, L., Bondarenko, I., O’Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., Davidson, N., Richards, J., Maio, M., Hauschild, A., Miller, W. H., Gascon, P., Lotem, M., Harmankaya, K., Ibrahim, R., … Wolchok, J. D. (2011). Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New England Journal of Medicine, 364(26), 2517–2526.CrossRefPubMed
20.
go back to reference van de Poll-Franse, L. V., Horevoorts, N., van Eenbergen, M., Denollet, J., Roukema, J. A., Aaronson, N. K., Vingerhoets, A., Coebergh, J. W., de Vries, J., Essink-Bot, M.-L., & Mols, F. (2011). The patient reported outcomes following initial treatment and long term evaluation of survivorship registry: scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts. European Journal of Cancer, 47(14), 2188–2194.CrossRefPubMed van de Poll-Franse, L. V., Horevoorts, N., van Eenbergen, M., Denollet, J., Roukema, J. A., Aaronson, N. K., Vingerhoets, A., Coebergh, J. W., de Vries, J., Essink-Bot, M.-L., & Mols, F. (2011). The patient reported outcomes following initial treatment and long term evaluation of survivorship registry: scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts. European Journal of Cancer, 47(14), 2188–2194.CrossRefPubMed
21.
go back to reference Pickard, A. S., Neary, M. P., & Cella, D. (2007). Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health and Quality of Life Outcomes, 5(1), 1–8.CrossRef Pickard, A. S., Neary, M. P., & Cella, D. (2007). Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health and Quality of Life Outcomes, 5(1), 1–8.CrossRef
22.
go back to reference Feng, Y.-S., Kohlmann, T., Janssen, M. F., & Buchholz, I. (2021). Psychometric properties of the EQ-5D-5L: A systematic review of the literature. Quality of Life Research, 30(3), 647–673.CrossRefPubMed Feng, Y.-S., Kohlmann, T., Janssen, M. F., & Buchholz, I. (2021). Psychometric properties of the EQ-5D-5L: A systematic review of the literature. Quality of Life Research, 30(3), 647–673.CrossRefPubMed
23.
go back to reference Osoba, D., Zee, B., Pater, J., Warr, D., Kaizer, L., & Latreille, J. (1994). Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Quality of Life Research, 3(5), 353–364.CrossRefPubMed Osoba, D., Zee, B., Pater, J., Warr, D., Kaizer, L., & Latreille, J. (1994). Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Quality of Life Research, 3(5), 353–364.CrossRefPubMed
24.
go back to reference Zigmond, A. S., & Snaith, R. P. (1983). The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica, 67(6), 361–370.CrossRefPubMed Zigmond, A. S., & Snaith, R. P. (1983). The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica, 67(6), 361–370.CrossRefPubMed
25.
go back to reference Custers, J. A., van den Berg, S. W., van Laarhoven, H. W., Bleiker, E. M., Gielissen, M. F., & Prins, J. B. (2014). The cancer worry scale: Detecting fear of recurrence in breast cancer survivors. Cancer Nursing, 37(1), E44–E50.CrossRefPubMed Custers, J. A., van den Berg, S. W., van Laarhoven, H. W., Bleiker, E. M., Gielissen, M. F., & Prins, J. B. (2014). The cancer worry scale: Detecting fear of recurrence in breast cancer survivors. Cancer Nursing, 37(1), E44–E50.CrossRefPubMed
26.
go back to reference Sangha, O., Stucki, G., Liang, M. H., Fossel, A. H., & Katz, J. N. (2003). The Self-Administered Comorbidity Questionnaire: A new method to assess comorbidity for clinical and health services research. Arthritis Care & Research: Official Journal of the American College of Rheumatology, 49(2), 156–163.CrossRef Sangha, O., Stucki, G., Liang, M. H., Fossel, A. H., & Katz, J. N. (2003). The Self-Administered Comorbidity Questionnaire: A new method to assess comorbidity for clinical and health services research. Arthritis Care & Research: Official Journal of the American College of Rheumatology, 49(2), 156–163.CrossRef
27.
go back to reference Razali, N. M., & Wah, Y. B. (2011). Power comparisons of shapiro-wilk, kolmogorov-smirnov, lilliefors and anderson-darling tests. Journal of Statistical Modeling and Analytics, 2(1), 21–33. Razali, N. M., & Wah, Y. B. (2011). Power comparisons of shapiro-wilk, kolmogorov-smirnov, lilliefors and anderson-darling tests. Journal of Statistical Modeling and Analytics, 2(1), 21–33.
29.
go back to reference Field, A. (2013). Discovering statistics using IBM SPSS statistics. Sage. Field, A. (2013). Discovering statistics using IBM SPSS statistics. Sage.
30.
go back to reference MacKinnon, D. P., Krull, J. L., & Lockwood, C. M. (2000). Equivalence of the mediation, confounding and suppression effect. Prevention science, 1(4), 173–181.CrossRefPubMedPubMedCentral MacKinnon, D. P., Krull, J. L., & Lockwood, C. M. (2000). Equivalence of the mediation, confounding and suppression effect. Prevention science, 1(4), 173–181.CrossRefPubMedPubMedCentral
31.
go back to reference Grandy, S., & Fox, K. M. (2008). EQ-5D visual analog scale and utility index values in individuals with diabetes and at risk for diabetes: Findings from the Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes (SHIELD). Health and quality of life outcomes, 6(1), 1–7.CrossRef Grandy, S., & Fox, K. M. (2008). EQ-5D visual analog scale and utility index values in individuals with diabetes and at risk for diabetes: Findings from the Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes (SHIELD). Health and quality of life outcomes, 6(1), 1–7.CrossRef
32.
go back to reference Allaire, J. (2012). RStudio: Integrated development environment for R. Boston, MA, 770(394), 165–171. Allaire, J. (2012). RStudio: Integrated development environment for R. Boston, MA, 770(394), 165–171.
34.
go back to reference J. S. Sekhon, 2008 Multivariate and propensity score matching software with automated balance optimization: the matching package for R. Journal of Statistical Software, Forthcoming J. S. Sekhon, 2008 Multivariate and propensity score matching software with automated balance optimization: the matching package for R. Journal of Statistical Software, Forthcoming
35.
go back to reference Harries, M., Malvehy, J., Lebbe, C., Heron, L., Amelio, J., Szabo, Z., & Schadendorf, D. (2016). Treatment patterns of advanced malignant melanoma (stage III–IV)–a review of current standards in Europe. European Journal of Cancer, 60, 179–189.CrossRefPubMed Harries, M., Malvehy, J., Lebbe, C., Heron, L., Amelio, J., Szabo, Z., & Schadendorf, D. (2016). Treatment patterns of advanced malignant melanoma (stage III–IV)–a review of current standards in Europe. European Journal of Cancer, 60, 179–189.CrossRefPubMed
36.
go back to reference Das, K. R., & Imon, A. (2016). A brief review of tests for normality. American Journal of Theoretical and Applied Statistics, 5(1), 5–12.CrossRef Das, K. R., & Imon, A. (2016). A brief review of tests for normality. American Journal of Theoretical and Applied Statistics, 5(1), 5–12.CrossRef
37.
go back to reference Schielzeth, H., Dingemanse, N. J., Nakagawa, S., Westneat, D. F., Allegue, H., Teplitsky, C., Réale, D., Dochtermann, N. A., Garamszegi, L. Z., & Araya-Ajoy, Y. G. (2020). Robustness of linear mixed-effects models to violations of distributional assumptions. Methods in ecology and evolution, 11(9), 1141–1152.CrossRef Schielzeth, H., Dingemanse, N. J., Nakagawa, S., Westneat, D. F., Allegue, H., Teplitsky, C., Réale, D., Dochtermann, N. A., Garamszegi, L. Z., & Araya-Ajoy, Y. G. (2020). Robustness of linear mixed-effects models to violations of distributional assumptions. Methods in ecology and evolution, 11(9), 1141–1152.CrossRef
39.
go back to reference Sprangers, M., & Schwartz, C. (1999). The challenge of response shift for quality-of-life-based clinical oncology research. Annals of oncology: Official Journal of the European Society for Medical Oncology, 10(7), 747–749.CrossRefPubMed Sprangers, M., & Schwartz, C. (1999). The challenge of response shift for quality-of-life-based clinical oncology research. Annals of oncology: Official Journal of the European Society for Medical Oncology, 10(7), 747–749.CrossRefPubMed
40.
go back to reference Vosoughi, E., Lee, J. M., Miller, J. R., Nosrati, M., Minor, D. R., Abendroth, R., Lee, J. W., Andrews, B. T., Leng, L. Z., Max, W., Leong, S. P., Kashani-Sabet, M., & Kim, K. B. (2018). Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies. BMC Cancer, 18(1), 1–7.CrossRef Vosoughi, E., Lee, J. M., Miller, J. R., Nosrati, M., Minor, D. R., Abendroth, R., Lee, J. W., Andrews, B. T., Leng, L. Z., Max, W., Leong, S. P., Kashani-Sabet, M., & Kim, K. B. (2018). Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies. BMC Cancer, 18(1), 1–7.CrossRef
41.
go back to reference Spagnolo, F., Picasso, V., Lambertini, M., Ottaviano, V., Dozin, B., & Queirolo, P. (2016). Survival of patients with metastatic melanoma and brain metastases in the era of MAP-kinase inhibitors and immunologic checkpoint blockade antibodies: A systematic review. Cancer Treatment Reviews, 45, 38–45.CrossRefPubMed Spagnolo, F., Picasso, V., Lambertini, M., Ottaviano, V., Dozin, B., & Queirolo, P. (2016). Survival of patients with metastatic melanoma and brain metastases in the era of MAP-kinase inhibitors and immunologic checkpoint blockade antibodies: A systematic review. Cancer Treatment Reviews, 45, 38–45.CrossRefPubMed
42.
go back to reference Dixon, S., Walters, S., Turner, L., & Hancock, B. (2006). Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: Results from randomised trial. British Journal of cancer, 94(4), 492–498.CrossRefPubMedPubMedCentral Dixon, S., Walters, S., Turner, L., & Hancock, B. (2006). Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: Results from randomised trial. British Journal of cancer, 94(4), 492–498.CrossRefPubMedPubMedCentral
Metagegevens
Titel
Health-state utilities in long-term advanced melanoma survivors comparable with the general population
Auteurs
M. D. Egeler
L. V. van de Poll-Franse
R. Tissier
A. Rogiers
M. J. Boers-Sonderen
A. J. van den Eertwegh
G. A. Hospers
J. W. B. de Groot
M. J. B. Aarts
E. Kapiteijn
D. Piersma
G. Vreugdenhil
A. A. van der Veldt
K. P. M. Suijkerbuijk
B. Neyns
K. J. Janssen
C. U. Blank
V. P. Retèl
A. H. Boekhout
Publicatiedatum
20-04-2023
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 9/2023
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-023-03427-9

Andere artikelen Uitgave 9/2023

Quality of Life Research 9/2023 Naar de uitgave